Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Laboratories Ltd (NYSE:RDY) reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.
雷迪博士实验室有限公司（纽约证券交易所代码：RDY）周二公布的2025年第二季度净收入为1.6亿美元，低于去年同期的1.77亿美元。
Revenue increased from $821 million to $957 million — almost a 16.6% jump.
收入从8.21亿美元增加到9.57亿美元，增长了近16.6％。
The strong revenue growth during the quarter was primarily driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).
本季度强劲的收入增长主要是由全球仿制药收入的增长推动的。连续增长是由新兴市场、印度、欧洲和制药服务和活性成分（PSAI）的全球仿制药收入带动的。
EBITDA for the quarter rose from $260 million to $272 million.
该季度的息税折旧摊销前利润从2.6亿美元增至2.72亿美元。
"We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands," said co-chair GV Prasad.
“我们又实现了一个不错的季度，并保持了各业务的增长势头。联席主席GV Prasad说，我们在未来的增长动力方面取得了进展，运营了与雀巢的合资企业，并完成了对Nicotinell和相关品牌的收购。
Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.
受销售量增加和新产品发布的推动，第二季度全球仿制药收入达到716卢比，同比增长17％。
North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.
北美销售额增长了17％（连续下降3％），达到373卢比。同比增长主要归因于销量的增加，但部分被价格下跌所抵消。连续下降是由于销量下降所致。
Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.
毛利率为59.6％（GG：63.1％，PSAI：30.0％），同比增长92个基点（基点），环比下降81个基点。同比增长是由于产品组合和管理费用杠杆率的改善，但部分被价格下跌所抵消。连续下降，主要是由于组合的变化。
Price Action: Dr. Reddy's Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.
价格走势：在周二最后一次盘前交易中，雷迪博士实验室上涨4.81％，至15.51美元。
- Short Squeeze – GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook
- 空头挤压——GlobalFoundries股价因第三季度盈利好转而飙升，第四季度前景强劲
